State Street Corporation filed a Schedule 13G with the SEC on November 10, 2026, disclosing beneficial ownership of shares of Allogene Therapeutics Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: State Street Corporation reported beneficial ownership of 16,326,197 shares of Allogene Therapeutics Inc. common stock.
  • Percent of class: The reported holdings represent 4.7% of the class of securities, according to the filing.
  • Shared voting power: State Street disclosed shared voting power over 16,065,094 shares, with sole voting power of 0.
  • Shared dispositive power: The filing reports shared dispositive power over 16,326,197 shares, with sole dispositive power of 0.
  • Subsidiaries involved: The filing identifies SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, and State Street Global Advisors Trust Company as the relevant subsidiaries through which the securities were acquired.
  • Event date: The date of the event requiring the filing is listed as September 30, 2026.

State Street Corporation's Schedule 13G Filing on Allogene Therapeutics Common Stock

State Street Corporation, organized in Massachusetts and headquartered at One Congress Street, Suite 1, Boston, MA 02114, filed a Schedule 13G disclosing its beneficial ownership position in Allogene Therapeutics Inc. (CUSIP: 019770106), a company whose principal executive offices are located at 210 East Grand Avenue, South San Francisco, California, 94080. The filing was signed by Alok Maheshwary, Senior Vice President, and dated November 9, 2026.

According to the filing, State Street's aggregate beneficial ownership stands at 16,326,197 shares, representing 4.7% of the class. The filing type is classified as "HC" (parent holding company or control person). State Street disclosed zero sole voting power and zero sole dispositive power, indicating that all voting and dispositive authority is held on a shared basis. Shared voting power covers 16,065,094 shares, while shared dispositive power extends to the full 16,326,197 shares reported.

The filing identifies three subsidiaries as the entities that acquired the securities on behalf of State Street: SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, and State Street Global Advisors Trust Company, each classified as an investment adviser (IA). The filing certifies, in accordance with SEC requirements, that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

State Street Corporation disclosed a 4.7% beneficial ownership position in Allogene Therapeutics Inc. common stock, totaling 16,326,197 shares as of September 30, 2026, held through three investment adviser subsidiaries with all authority exercised on a shared basis.